Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00117611 · ClinicalTrials.gov registry record · Phase 4
Xolair in Patients With Chronic Sinusitis
A Phase 4 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
NCT00117611: Completed Phase 4 study, sponsored by University of Chicago.
NCT00117611 is a Phase 4 study that has completed, run by University of Chicago. The registered enrollment target is 14 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00117611, a Phase 4 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
Interventions
- DRUG Anti-IgE antibody omalizumab or placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2005-07 |
| Est. Completion | 2009-01 |
| Phase | Phase 4 |
What the finished NCT00117611 record still lists
NCT00117611 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Anti-IgE antibody omalizumab or placebo is the first listed.
NCT00117611 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00117611 about?
NCT00117611 is a clinical study titled "Xolair in Patients With Chronic Sinusitis". The purpose of this study is to determine if treatment with the anti-IgE antibody, Xolair (omalizumab), will improve objective and subjective evidence of chronic sinusitis.
What is the current status of trial NCT00117611?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2005-07. Estimated completion is 2009-01.
What interventions are being tested in trial NCT00117611?
The interventions under investigation include: Anti-IgE antibody omalizumab or placebo (DRUG).
Who is sponsoring clinical trial NCT00117611?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00117611's enrollment target sits among peer trials
14 1901st of 2000 higher than 91 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia